Cybin Inc. (HELP)
NASDAQ: HELP · Real-Time Price · USD
8.14
+0.23 (2.91%)
At close: Jul 30, 2026, 4:00 PM EDT
8.11
-0.03 (-0.37%)
After-hours: Jul 30, 2026, 7:52 PM EDT
Cybin Employees
Cybin had 100 employees as of March 31, 2026. The number of employees increased by 50 or 100.00% compared to the previous year.
Employees
100
Change (1Y)
50
Growth (1Y)
100.00%
Revenue / Employee
n/a
Profits / Employee
-$1,479,980
Market Cap
504.55M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Mar 31, 2026 | 100 | 50 | 100.00% |
| Mar 31, 2025 | 50 | 0 | - |
| Mar 31, 2024 | 50 | 0 | - |
| Mar 31, 2023 | 50 | 0 | - |
| Mar 31, 2022 | 50 | 12 | 31.58% |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Valneva SE | 674 |
| Ginkgo Bioworks Holdings | 485 |
| 4D Molecular Therapeutics | 196 |
| Adlai Nortye | 109 |
| Artiva Biotherapeutics | 106 |
| Verastem | 102 |
| Assembly Biosciences | 73 |
| Rezolute | 68 |
HELP News
- 3 days ago - Helus Pharma initiated with an Overweight at Wells Fargo - TheFly
- 9 days ago - Helus Pharma completes enrollment in Phase 3 APPROACH study of HLP003 - TheFly
- 9 days ago - Helus Pharma Completes Enrollment in Phase 3 APPROACH Study of HLP003 in Adjunctive Treatment of Major Depressive Disorder Ahead of Schedule - GlobeNewsWire
- 13 days ago - Helus Pharma price target lowered to $45 from $48 at Guggenheim - TheFly
- 16 days ago - Helus Pharma price target lowered to $15 from $30 at Alliance Global - TheFly
- 21 days ago - Psychedelic: Compass Pathways reports six-month data for psilocybin drug - TheFly
- 21 days ago - Helus Pharma price target lowered to $70 from $95 at H.C. Wainwright - TheFly
- 4 weeks ago - Helus Pharma price target lowered to $42 from $45 at Canaccord - TheFly